Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

A non-opioid pain medication made by Vertex Pharmaceuticals ... safe and effective alternatives to opioids for pain management." Vertex said that almost 10% of patients initially given opioids ...

we have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” Vertex’s chief executive, Reshma Kewalramani, said in a statement. Soon after the ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

Vertex’s medicine could therefore be an “amazing” addition, he said, as it may offer some relief not only after surgery, but in everyday pain management as well. Journavx might dull ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

Vertex's Chronic Pain Ambitions Hit Roadblock with LSR Data So much of Journavx's potential lies in chronic pain management. In December, Vertex revealed Phase 2 data evaluating Journavx in ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

Reshma Kewalramani, CEO and president of Vertex, called the drug's approval "a historic milestone" in a statement. "We have the opportunity to change the paradigm of acute pain management and ...

Vertex secured FDA approval for JOURNAVX, a non-opioid pain treatment, marking a significant advancement in pain management. The company reached a reimbursement agreement with NHS England for ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in ... transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical ...